Business Context and Reporting Period
Company: AptarGroup, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2004
Business Overview: AptarGroup operates in the packaging components industry, developing, manufacturing, and selling consumer product dispensing systems. The company is organized into two reportable segments: Dispensing Systems and SeaquistPerfect. Operations are global, with significant exposure to foreign currency fluctuations, particularly the Euro.
Key Financial Metrics
| Metric | Q2 2004 | Q2 2003 | YTD 2004 | YTD 2003 |
|---|---|---|---|---|
| Net Sales | $311.8 million | $288.1 million | $627.4 million | $553.2 million |
| Operating Income | $35.4 million | $33.4 million | $67.1 million | $63.8 million |
| Net Income | $22.8 million | $21.3 million | $44.0 million | $40.6 million |
| Diluted EPS | $0.61 | $0.58 | $1.18 | $1.11 |
| Operating Margin | 11.4% | 11.6% | 10.7% | 11.5% |
| Net Cash from Operations (YTD) | $82.0 million (vs. $56.2 million YTD 2003) | |||
| Cash and Equivalents | $187.1 million (as of June 30, 2004) | |||
| Total Debt (Short & Long Term) | $215.9 million (as of June 30, 2004) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% in Q2 and 13% YTD compared to the prior year. Approximately half of this growth is attributed to favorable foreign currency exchange rates. Organic growth was driven by the food/beverage market (+28%) and personal care market (+5% to +7%).
- Margin Compression: Cost of sales as a percentage of net sales increased to 66.1% in Q2 (from 65.4% in 2003) and 66.6% YTD (from 65.2%). This was driven by rising raw material costs (plastic resin and metal), price competition in the fragrance/cosmetic market, and the strengthening Euro.
- One-Time Items: The company recorded approximately $400,000 in shut-down and severance charges in Q2 related to closing a U.S. mold manufacturing facility. Additionally, a $1 million gain on the sale of a building in Q1 offset some costs.
- Pharmaceutical Segment: Sales to the pharmaceutical market decreased 1% in Q2 due to a shift in product mix (lower-priced metered dose valves vs. higher-priced spray pumps) and a specific customer reducing inventory levels. However, YTD sales increased 5% due to a $7 million increase in custom tooling sales for a project that was subsequently canceled by the customer.
Guidance, Outlook, and Risks
- Outlook: Management expects positive momentum to continue into the third quarter. Sales are projected to increase across all markets, including a rebound in the pharmaceutical sector from a generic pharmaceutical customer.
- Earnings Guidance: Excluding potential tax refunds, diluted EPS for Q3 2004 is anticipated to be in the range of $0.62 to $0.67, compared to $0.51 in Q3 2003.
- Capital Allocation: The Board increased the quarterly dividend to $0.15 per share (from $0.07) and authorized an additional 2 million shares for repurchase (total authorization now 5 million shares). Capital expenditures for 2004 are estimated at $110 million.
- Liquidity: The company maintains a $150 million revolving credit facility with $102 million available as of June 30, 2004. Net debt to net capital ratio decreased to approximately 3%.
- Risks: Key risks include significant fluctuations in currency exchange rates (particularly the Euro), raw material cost volatility, price competition from Asian suppliers, and the timing of customer product launches.
Investor Verification Checklist
- Currency Impact: Verify the extent to which reported revenue growth is organic versus driven by the weakening U.S. dollar against the Euro.
- Pharmaceutical Customer: Confirm the status of the canceled custom tooling project and the trajectory of the customer who reduced inventory levels in late 2003.
- Raw Material Costs: Monitor the ability to pass on increased plastic resin and metal costs to customers to protect margins.
- Facility Closure: Track the completion of the U.S. mold manufacturing facility shutdown and the realization of associated cost savings.
- Dividend Sustainability: Assess the impact of the doubled dividend rate on future cash flow and capital expenditure flexibility.